FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Michael Blute

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Prostate Specific Antigen

Physiology

Disease Progression

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Michael L Blute; Arvin K George; Igor I Lobko; Daniel M Moreira; Zhamshid Okhunov; Suzanne Sunday; Manish Vira
Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications.
Joel H Hillelsohn; Mahyar Kashan; Robert Moldwin; Zhamshid Okhunov; Michael L Blute; Brian Duty; Richard N Ashley
Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures.
R Houston Thompson; Michael L Blute; Amr Fergany; Igor Frank; Inderbir S Gill; Brian R Lane; Bradley C Leibovich; Christine M Lohse; Steven C Campbell
Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Michael Blute (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Michael L Blute; Arvin K George; Igor I Lobko; Daniel M Moreira; Zhamshid Okhunov; Suzanne Sunday; Manish Vira
Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications.
BJU international 2013;111(4 Pt B):E181-5.
2012: Joel H Hillelsohn; Mahyar Kashan; Robert Moldwin; Zhamshid Okhunov; Michael L Blute; Brian Duty; Richard N Ashley
Variability of transrectal ultrasound-guided prostate biopsy prophylactic measures.
The Canadian journal of urology 2012;19(6):6573-7.
2012: R Houston Thompson; Michael L Blute; Amr Fergany; Igor Frank; Inderbir S Gill; Brian R Lane; Bradley C Leibovich; Christine M Lohse; Steven C Campbell
Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney.
Urology 2012;79(2):356-60.
2012: Michael L Blute; Arvin George; Amin Herati; Louis R Kavoussi; Arun Srinivasian; Manish Vira; Lee Richstone
Intracorporeal neobladder reconstruction: pressure-flow urodyamic studies in cadaveric orthotopic neobladders.
BJU international 2012;109(3):434-6.
2011: Umberto Capitanio; Peter Mulders; Jean-Jacques Patard; Paul Russo; Urs E Studer; Frank Becker; Michael L Blute; Hein Van Poppel
Lymph node dissection in renal cell carcinoma.
European urology 2011;60(6):1212-20.
2011: Brant A Inman; R Jeffrey Karnes; Bradley C Leibovich; Joseph W Akornor; Michael L Blute; Stephen A Boorjian; Igor Frank; Eric J Bergstralh
Dynamic prediction of metastases after radical prostatectomy for prostate cancer.
BJU international 2011;108(11):1762-8.
2011: Michael L Blute
Editorial comment.
Urology 2011;78(3):619; author reply 619.
2011: M Adam Childs; Michael L Blute; Rodney H Breau; John C Cheville; Christine M Lohse; R Houston Thompson; Eric C Umbreit; Bradley C Leibovich
Metachronous renal tumours after surgical management of oncocytoma.
BJU international 2011;108(6):816-9.
2011: Daher C Chade; Angel M Cronin; Marcos Dall'Oglio; Michael L Blute; Alberto Briganti; Martin E Gleave; Guilherme Godoy; Antonio Hurtado-coll; Steven Joniau; R Jeffrey Karnes; Francesco Montorsi; Caroline J Savage; Peter T Scardino; Shahrokh F Shariat; Miguel Srougi; Henk G van der Poel; Hendrik Van Poppel; James A Eastham
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.
European urology 2011;60(2):205-10.
2011: Stephen A Boorjian; Eric J Bergstralh; Michael L Blute; Eric M Horwitz; R Jeffrey Karnes; Laureano J Rangel; Rosalia Viterbo; Mark K. Buyyounouski
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
Cancer 2011;117(13):2883-91.
2011: Angela L Alt; Stephen A Boorjian; Brian A Costello; Bradley C Leibovich; Christine M Lohse; Michael L Blute
Survival after complete surgical resection of multiple metastases from renal cell carcinoma.
Cancer 2011;117(13):2873-82.
2011: Bryan Bruner; Bradley C Leibovich; Christine M Lohse; Rodney H Breau; Michael L Blute
Renal nephrometry score is associated with urine leak after partial nephrectomy.
BJU international 2011;108(1):67-72.
2011: Stephen A Boorjian; R Houston Thompson; Matthew K Tollefson; Laureano J Rangel; Erik J Bergstralh; Michael L Blute; R Jeffrey Karnes
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.
European urology 2011;59(6):893-9.
2011: Matthew K Tollefson; Matthew T Gettman; Michael L Blute; Erik J Bergstralh; Laureano J Rangel; R Jeffrey Karnes
Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy.
Urology 2011;77(5):1161-5.
2011: Stephen A Boorjian; Michael L Blute
Editorial comment.
Urology 2011;77(4):950-1.
2011: Xavier Frigola; Brant A Inman; Christine M Lohse; Christopher J Krco; John C Cheville; R Houston Thompson; Bradley Leibovich; Michael L Blute; Haidong Dong; Eugene D Kwon
Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(7):1915-23.
2011: Brian Shuch; Paul L Crispen; Bradley C Leibovich; Jeff C Larochelle; Frederic Pouliot; Allan J Pantuck; Weiqing Liu; Maxime Crepel; Anne Schuckman; Jerome Rigaud; Oliver Bouchot; Jean-Jacques Patard; Donald Skinner; Arie S Belldegrun; Michael L Blute
Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?
BJU international 2011;107(5):724-8.
2011: Sameer A Siddiqui; Stephen A Boorjian; Michael L Blute; Laureano J Rangel; Erik J Bergstralh; R Jeffrey Karnes; Igor Frank
Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
BJU international 2011;107(3):383-8.
2011: Mark S Shimko; Matthew K Tollefson; Eric C Umbreit; Sara A Farmer; Michael L Blute; Igor Frank
Long-term complications of conduit urinary diversion.
The Journal of urology 2011;185(2):562-7.
2011: Rodney H Breau; Paul L Crispen; Sarah M Jenkins; Michael L Blute; Bradley C Leibovich
Treatment of patients with small renal masses: a survey of the American Urological Association.
The Journal of urology 2011;185(2):407-13.
2011: Paul L Crispen; Rodney H Breau; Cristine Allmer; Christine M Lohse; John C Cheville; Bradley C Leibovich; Michael L Blute
Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates.
European urology 2011;59(1):18-23.
2010: Matthew K Tollefson; Stephen A Boorjian; Christine M Lohse; Michael L Blute; Bradley C Leibovich
The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma.
BJU international 2010;106(11):1638-42.
2010: Thomas D Atwell; Matthew R Callstrom; Michael A Farrell; Grant D Schmit; David A Woodrum; Bradley C Leibovich; George K Chow; David E Patterson; Michael L Blute; J William Charboneau
Percutaneous renal cryoablation: local control at mean 26 months of followup.
The Journal of urology 2010;184(4):1291-5.
2010: Matthew K Tollefson; Michael L Blute
Editorial comment.
Urology 2010;76(3):721-2; discussion 722.
2010: R Houston Thompson; Brian R Lane; Christine M Lohse; Bradley C Leibovich; Amr Fergany; Igor Frank; Inderbir S Gill; Michael L Blute; Steven C Campbell
Every minute counts when the renal hilum is clamped during partial nephrectomy.
European urology 2010;58(3):340-5.
2010: Matthew K Tollefson; Michael L Blute; Laureano Rangel; R Jeffrey Karnes; Igor Frank
Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
The Journal of urology 2010;184(3):925-9.
2010: Rodney H Breau; Michael L Blute
Surgery for renal cell carcinoma metastases.
Current opinion in urology 2010;20(5):375-81.
2010: R Houston Thompson; Brian R Lane; Christine M Lohse; Bradley C Leibovich; Amr Fergany; Igor Frank; Inderbir S Gill; Steven C Campbell; Michael L Blute
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney.
European urology 2010;58(3):331-6.
2010: Paul L Crispen; Mitra R Tabidian; Cristine Allmer; Christine M Lohse; Rodney H Breau; Michael L Blute; John C Cheville; Bradley C Leibovich
Unclassified renal cell carcinoma: impact on survival following nephrectomy.
Urology 2010;76(3):580-6.
2010: Grant D Schmit; Thomas D Atwell; Matthew R Callstrom; Michael A Farrell; Bradley C Leibovich; David E Patterson; George K Chow; Michael L Blute; J William Charboneau
Percutaneous cryoablation of renal masses >or=3 cm: efficacy and safety in treatment of 108 patients.
Journal of endourology / Endourological Society 2010;24(8):1255-62.
2010: Eric C Umbreit; Paul L Crispen; Mark S Shimko; Sara A Farmer; Michael L Blute; Igor Frank
Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma.
Cancer 2010;116(14):3399-407.
2010: Matthew K Tollefson; Amy E Krambeck; Bradley C Leibovich; Michael L Blute; George K Chow
Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient.
Urology 2010;75(6):1373-7.
2010: Matthew K Tollefson; Michael L Blute; Laureano J Rangel; Erik J Bergstralh; Stephen A Boorjian; R Jeffrey Karnes
The effect of Gleason score on the predictive value of prostate-specific antigen doubling time.
BJU international 2010;105(10):1381-5.
2010: Bradley C Leibovich; Christine M Lohse; Paul L Crispen; Stephen A Boorjian; R Houston Thompson; Michael L Blute; John C Cheville
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.
The Journal of urology 2010;183(4):1309-15.
2010: Michael L Blute
Editorial comment.
The Journal of urology 2010;183(4):1365.
2010: Matthew T Gettman; Michael L Blute
Radical prostatectomy: does surgical technique influence margin control?
Urologic oncology 2010;28(2):219-25.
2010: Stephen A Boorjian; R Jeffrey Karnes; Paul L Crispen; Rachel E Carlson; Laureano J Rangel; Eric J Bergstralh; Michael L Blute
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era.
The Journal of urology 2010;183(3):1003-9.
2010: Rodney H Breau; Paul L Crispen; Rafael E Jimenez; Christine M Lohse; Michael L Blute; Bradley C Leibovich
Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy.
The Journal of urology 2010;183(3):903-8.
2010: Eric C Umbreit; Eric J Dozois; Paul L Crispen; Matthew K Tollefson; R Jeffrey Karnes; Michael L Blute
Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life.
Journal of the American College of Surgeons 2010;210(2):232-9.
2010: Matthew K Tollefson; Michael L Blute; Sara A Farmer; Igor Frank
Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma.
The Journal of urology 2010;183(1):81-6.
2010: R Jeffrey Karnes; Tadashi Hatano; Michael L Blute; Robert P Myers
Radical prostatectomy for high-risk prostate cancer.
Japanese journal of clinical oncology 2010;40(1):3-9.
2010: Michael L Blute
Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
European urology 2010;57(1):110-1.
2009: Rodney H Breau; John C Cheville; Christine M Lohse; Eugene D Kwon; Michael L Blute
Re: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. T. Klatte, J. W. Said, M. de Martino, J. Larochelle, B. Shuch, J. Y. Rao, G. V. Thomas, F. F. Kabbinavar, A. S. Belldegrun and A. J. Pantuck. J Urol 2009; 181: 1558-1564.
The Journal of urology 2009;182(6):2979-80; author reply 2980-1.
2009: R Houston Thompson; Sameer Siddiqui; Christine M Lohse; Bradley C Leibovich; Paul Russo; Michael L Blute
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors.
The Journal of urology 2009;182(6):2601-6.
2009: Stephen A Boorjian; R Jeffrey Karnes; Paul L Crispen; Laureano J Rangel; Eric J Bergstralh; Michael L Blute
Radiation therapy after radical prostatectomy: impact on metastasis and survival.
The Journal of urology 2009;182(6):2708-14.
2009: Paul L Crispen; Michael L Blute
Editorial comment.
Urology 2009;74(5):1046; author reply 1046-7.
2009: Steven C Campbell; Andrew C Novick; Arie Belldegrun; Michael L Blute; George K Chow; Ithaar H Derweesh; Martha M Faraday; Jihad H Kaouk; Raymond J Leveillee; Surena F Matin; Paul Russo; Robert G Uzzo
Guideline for management of the clinical T1 renal mass.
The Journal of urology 2009;182(4):1271-9.
2009: Stephen A Boorjian; Michael L Blute
Surgery for vena caval tumor extension in renal cancer.
Current opinion in urology 2009;19(5):473-7.
2009: Sameer A Siddiqui; Igor Frank; John C Cheville; Christine M Lohse; Bradley C Leibovich; Michael L Blute
Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol.
BJU international 2009;104(6):778-85.
2009: Michael L Blute
Editorial comment.
Urology 2009;74(1):159; author reply 160.
2009: Michael L Blute
No proof of inferiority: open radical retropubic prostatectomy remains state-of-the-art surgical technique for localized prostate cancer.
The Journal of urology 2009;181(6):2421-3.
2009: Alberto Briganti; Michael L Blute; James H Eastham; Markus Graefen; Axel Heidenreich; Jeffrey R Karnes; Francesco Montorsi; Urs E Studer
Pelvic lymph node dissection in prostate cancer.
European urology 2009;55(6):1251-65.
2009: Alexander S Parker; Bradley C Leibovich; Christine M Lohse; Yuri Sheinin; Susan M Kuntz; Jeanette E Eckel-Passow; Michael L Blute; Eugene D Kwon
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma.
Cancer 2009;115(10):2092-103.
2009: Paul L Crispen; Michael L Blute
Editorial comment on: Renal angiomyolipoma: long-term results following selective arterial embolization.
European urology 2009;55(5):1161-2.
2009: Grant Chavin; Yuri Sheinin; Paul L Crispen; Stephen A Boorjian; Timothy J Roth; Laureano Rangel; Michael L Blute; Thomas J Sebo; Don J Tindall; Eugene D Kwon; R Jeffrey Karnes
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(6):2174-80.
2009: Alberto Briganti; Jeffrey R Karnes; Luigi Da Pozzo; Cesare Cozzarini; Andrea Gallina; Nazareno Suardi; Marco Bianchi; Massimo Freschi; Claudio Doglioni; Ferruccio Fazio; Patrizio Rigatti; Francesco Montorsi; Michael L Blute
Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.
European urology 2009;55(2):261-70.
2009: Paul L Crispen; Michael L Blute
Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies?
European urology 2009;55(2):307-9.
2009: Amy E Krambeck; David S DiMarco; Laureano Rangel; Eric J Bergstralh; Robert P Myers; Michael L Blute; Matthew T Gettman
Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques.
BJU international 2009;103(4):448-53.
2008: Candace F Granberg; Stephen A Boorjian; Paul L Crispen; Matthew K Tollefson; Sara A Farmer; Igor Frank; Michael L Blute
Functional and oncological outcomes after orthotopic neobladder reconstruction in women.
BJU international 2008;102(11):1551-5.
2008: Bradley C Leibovich; Michael L Blute
Lymph node dissection in the management of renal cell carcinoma.
The Urologic clinics of North America 2008;35(4):673-8; viii.
2008: Paul L Crispen; Stephen A Boorjian; Christine M Lohse; Thomas S Sebo; John C Cheville; Michael L Blute; Bradley C Leibovich
Outcomes following partial nephrectomy by tumor size.
The Journal of urology 2008;180(5):1912-7.
2008: R Houston Thompson; Amy E Krambeck; Christine M Lohse; Daniel S Elliott; David E Patterson; Michael L Blute
Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract.
BJU international 2008;102(9):1107-10.
2008: Brant A Inman; Judson D Davies; Laureano J Rangel; Erik J Bergstralh; Eugene D Kwon; Michael L Blute; R Jeffrey Karnes; Bradley C Leibovich
Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL.
Cancer 2008;113(7):1544-51.
2008: Stephen A Boorjian; Paul L Crispen; Christine M Lohse; Bradley C Leibovich; Michael L Blute
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses.
European urology 2008;54(4):855-63.
2008: Stephen A Boorjian; Michael L Blute
Surgical management of high risk prostate cancer: the Mayo Clinic experience.
Urologic oncology 2008;26(5):530-2.
2008: Paul L Crispen; Yuri Sheinin; Timothy J Roth; Christine M Lohse; Susan M Kuntz; Xavier Frigola; R Houston Thompson; Stephen A Boorjian; Haidong Dong; Bradley C Leibovich; Michael L Blute; Eugene D Kwon
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(16):5150-7.
2008: R Houston Thompson; Xingxing Zang; Christine M Lohse; Bradley C Leibovich; Susan F Slovin; Victor E Reuter; John C Cheville; Michael L Blute; Paul Russo; Eugene D Kwon; James P Allison
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage.
Cancer research 2008;68(15):6054-8.
2008: Jonathan C Routh; Douglas R Bacon; Bradley C Leibovich; Horst Zincke; Michael L Blute; Igor Frank
How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery.
BJU international 2008;102(3):301-4.
2008: R Houston Thompson; John C Cheville; Bradley C Leibovich; Michael L Blute
Re: Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. V. Margulis, P. Tamboli, S. F. Matin, M. Meisner, D. A. Swanson and C. G. Wood. J Urol 2007; 178: 1878-1882.
The Journal of urology 2008;180(1):409; author reply 409-10.
2008: Stephen A Boorjian; Paul L Crispen; Christine M Lohse; Bradley C Leibovich; Michael L Blute
Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy.
The Journal of urology 2008;180(1):99-103; discussion 103.
2008: Candace F Granberg; Stephen A Boorjian; Hartzell V Schaff; Thomas A Orszulak; Bradley C Leibovich; Christine M Lohse; John C Cheville; Michael L Blute
Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass.
Urology 2008;72(1):148-52.
2008: Cristiane M Ida; Xiaoke Wang; Michele R Erickson-Johnson; Doris E Wenger; Michael L Blute; Antonio G Nascimento; Andre M Oliveira
Primary retroperitoneal lipoma: a soft tissue pathology heresy?: report of a case with classic histologic, cytogenetics, and molecular genetic features.
The American journal of surgical pathology 2008;32(6):951-4.
2008: R Jeffrey Karnes; Michael L Blute
Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus.
Nature clinical practice. Urology 2008;5(6):329-39.
2008: Ofer Yossepowitch; R Houston Thompson; Bradley C Leibovich; Scott E Eggener; Joseph A Pettus; Eugene D Kwon; Harry W Herr; Michael L Blute; Paul Russo
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes.
The Journal of urology 2008;179(6):2158-63.
2008: Ajay Nehra; Rajeev Kumar; Sanjay Ramakumar; Robert P Myers; Michael L Blute; Michael A McKusick
Pharmacoangiographic evidence of the presence and anatomical dominance of accessory pudendal artery(s).
The Journal of urology 2008;179(6):2317-20.
2008: Ganesh V Raj; R Houston Thompson; Bradley C Leibovich; Michael L Blute; Paul Russo; Michael W Kattan
Preoperative nomogram predicting 12-year probability of metastatic renal cancer.
The Journal of urology 2008;179(6):2146-51; discussion 2151.
2008: Thomas D Atwell; Michael A Farrell; Bradley C Leibovich; Matthew R Callstrom; George K Chow; Michael L Blute; J William Charboneau
Percutaneous renal cryoablation: experience treating 115 tumors.
The Journal of urology 2008;179(6):2136-40; discussion 2140-1.
2008: Michael L Blute
Radical prostatectomy by open or laparoscopic/robotic techniques: an issue of surgical device or surgical expertise?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(14):2248-9.
2008: Sameer A Siddiqui; Stephen A Boorjian; Brant A Inman; Stephanie M Bagniewski; Erik J Bergstralh; Michael L Blute
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
The Journal of urology 2008;179(5):1830-7; discussion 1837.
2008: Richard A Ashley; Brant A Inman; Jonathan C Routh; Lance A Mynderse; Matthew T Gettman; Michael L Blute
Reassessing the diagnostic yield of saturation biopsy of the prostate.
European urology 2008;53(5):976-81.
2008: R Houston Thompson; Bradley C Leibovich; R Jeffrey Karnes; Erik J Bergstralh; Michael L Blute
Radical retropubic prostatectomy in immunosuppressed transplant recipients.
The Journal of urology 2008;179(4):1349-52; discussion 1352-3.
2008: Stephen A Boorjian; R Jeffrey Karnes; Laureano Rangel; Erik J Bergstralh; Michael L Blute
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.
The Journal of urology 2008;179(4):1354-60; discussion 1360-1.
2008: R Houston Thompson; Amy E Krambeck; Christine M Lohse; Daniel S Elliott; David E Patterson; Michael L Blute
Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys.
Urology 2008;71(4):713-7.
2008: Shomik Sengupta; Christopher L Amling; Anthony V D'Amico; Michael L Blute
Prostate specific antigen kinetics in the management of prostate cancer.
The Journal of urology 2008;179(3):821-6.
2008: James S Magera; Igor Frank; Christine M Lohse; Bradley C Leibovich; John C Cheville; Michael L Blute
Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant.
The Journal of urology 2008;179(3):853-6.
2008: James S Magera; Bradley C Leibovich; Christine M Lohse; Shomik Sengupta; John C Cheville; Eugene D Kwon; Michael L Blute
Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma.
Urology 2008;71(2):278-82.
2008: R Houston Thompson; Stephen A Boorjian; Christine M Lohse; Bradley C Leibovich; Eugene D Kwon; John C Cheville; Michael L Blute
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy.
The Journal of urology 2008;179(2):468-71; discussion 472-3.
2008: Nathan E Hoffmann; Michael D Gillett; John C Cheville; Christine M Lohse; Bradley C Leibovich; Michael L Blute
Differences in organ system of distant metastasis by renal cell carcinoma subtype.
The Journal of urology 2008;179(2):474-7.
2008: Stephen A Boorjian; R Jeffrey Karnes; Laureano Rangel; Erik J Bergstralh; Igor Frank; Michael L Blute
Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
BJU international 2008;101(3):299-304.
2008: Paul L Crispen; Christine M Lohse; Michael L Blute
Multifocal renal cell carcinoma: clinicopathologic features and outcomes for tumors
Advances in urology 2008;():518091.

2008: Shomik Sengupta; Michael L Blute; Stephanie M Bagniewski; Brant A Inman; Bradley C Leibovich; Jeffrey M Slezak; Robert P Myers; Horst Zincke
After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
BJU international 2008;101(2):170-4.
2007: Stephen A Boorjian; Igor Frank; Brant Inman; Christine M Lohse; John C Cheville; Bradley C Leibovich; Michael L Blute
The role of partial nephrectomy for the management of sporadic renal angiomyolipoma.
Urology 2007;70(6):1064-8.
2007: W Scott Webster; R Houston Thompson; John C Cheville; Christine M Lohse; Michael L Blute; Bradley C Leibovich
Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma.
Urology 2007;70(5):900-4; discussion 904.
2007: Richard A Ashley; Brant A Inman; Jonathan C Routh; Amy E Krambeck; Sameer A Siddiqui; Lance A Mynderse; Matthew T Gettman; Michael L Blute
Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial.
Cancer 2007;110(8):1708-14.
2007: Candace F Granberg; Amy E Krambeck; Bradley C Leibovich; Igor Frank; Christine M Lohse; Matthew T Gettman; Michael L Blute; George C Chow
Potential underdetection of pT(3a) renal-cell carcinoma with laparoscopic morcellation.
Journal of endourology / Endourological Society 2007;21(10):1183-6.
2007: R Houston Thompson; Michael L Blute
At what point does warm ischemia cause permanent renal damage during partial nephrectomy?
European urology 2007;52(4):961-3.
2007: Amy E Krambeck; R Houston Thompson; Christine M Lohse; David E Patterson; Daniel S Elliott; Michael L Blute
Imperative indications for conservative management of upper tract transitional cell carcinoma.
The Journal of urology 2007;178(3 Pt 1):792-6; discussion 796-7.
2007: Stephen A Boorjian; R Houston Thompson; Sameer Siddiqui; Stephanie M Bagniewski; Erik J Bergstralh; R Jeffrey Karnes; Igor Frank; Michael L Blute
Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
The Journal of urology 2007;178(3 Pt 1):864-70; discussion 870-1.
2007: Timothy J Roth; Yuri Sheinin; Christine M Lohse; Susan M Kuntz; Xavier Frigola; Brant A Inman; Amy E Krambeck; Maureen E McKenney; R Jeffrey Karnes; Michael L Blute; John C Cheville; Thomas J Sebo; Eugene D Kwon
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy.
Cancer research 2007;67(16):7893-900.
2007: Michael L Blute; Stephen A Boorjian; Bradley C Leibovich; Christine M Lohse; Igor Frank; R Jeffrey Karnes
Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy.
The Journal of urology 2007;178(2):440-5; discussion 444.
2007: R Houston Thompson; Michael L Blute; Jeffrey M Slezak; Erik J Bergstralh; Bradley C Leibovich
Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
The Journal of urology 2007;178(2):459-63; discussion 463.
2007: Sameer A Siddiqui; Lance A Mynderse; Horst Zincke; Nathan E Hoffmann; John R Lobo; Torrence M Wilson; Akira Kawashima; Brian J Davis; Michael L Blute
Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience.
Urology 2007;70(1):80-5.
2007: Matthew T Gettman; Michael L Blute
Transvesical peritoneoscopy: initial clinical evaluation of the bladder as a portal for natural orifice translumenal endoscopic surgery.
Mayo Clinic proceedings. Mayo Clinic 2007;82(7):843-5.
2007: R Houston Thompson; Michael L Blute; Amy E Krambeck; Christine M Lohse; James S Magera; Bradley C Leibovich; Eugene D Kwon; Igor Frank; John C Cheville
Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion.
The American journal of surgical pathology 2007;31(7):1089-93.
2007: Inderbir S Gill; Louis R Kavoussi; Brian R Lane; Michael L Blute; Denise Babineau; Jose R Colombo; Igor Frank; Sompol Permpongkosol; Christopher J Weight; Jihad H Kaouk; Michael W Kattan; Andrew C Novick
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors.
The Journal of urology 2007;178(1):41-6.
2007: Michael L Blute
Nephron-sparing surgery: the 'gold standard' treatment for small renal cortical tumors.
Nature clinical practice. Urology 2007;4(6):300-1.
2007: Julie M Cunningham; Scott J Hebbring; Shannon K McDonnell; Mine S Cicek; G Bryce Christensen; Liang Wang; Steven J Jacobsen; James Cerhan; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(5):969-78.
2007: Stephen A Boorjian; Shomik Sengupta; Michael L Blute
Renal cell carcinoma: vena caval involvement.
BJU international 2007;99(5 Pt B):1239-44.
2007: Amy E Krambeck; R Houston Thompson; Christine M Lohse; David E Patterson; Joseph W Segura; Horst Zincke; Daniel S Elliott; Michael L Blute
Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma.
The Journal of urology 2007;177(5):1721-6.
2007: Matthew K Tollefson; Jeffrey M Slezak; Bradley C Leibovich; Horst Zincke; Michael L Blute
Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Mayo Clinic proceedings. Mayo Clinic 2007;82(4):422-7.
2007: Liang Wang; Shannon K McDonnell; Joshua P Slusser; Scott J Hebbring; Julie M Cunningham; Steven J Jacobsen; James Cerhan; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer.
Cancer research 2007;67(7):2944-50.
2007: Sameer A Siddiqui; Xavier Frigola; Sandra Bonne-Annee; Maria Mercader; Susan M Kuntz; Amy E Krambeck; Shomik Sengupta; Haidong Dong; John C Cheville; Christine M Lohse; Christopher J Krco; W Scott Webster; Bradley C Leibovich; Michael L Blute; Keith L Knutson; Eugene D Kwon
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2075-81.
2007: Thomas D Atwell; Michael A Farrell; Matthew R Callstrom; J William Charboneau; Bradley C Leibovich; David E Patterson; George K Chow; Michael L Blute
Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience.
Radiology 2007;243(1):276-83.
2007: R Houston Thompson; Haidong Dong; Christine M Lohse; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1757-61.
2007: Amy E Krambeck; Haidong Dong; R Houston Thompson; Susan M Kuntz; Christine M Lohse; Bradley C Leibovich; Michael L Blute; Thomas J Sebo; John C Cheville; Alexander S Parker; Eugene D Kwon
Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1749-56.
2007: R Houston Thompson; Bradley C Leibovich; Christine M Lohse; John C Cheville; Horst Zincke; Michael L Blute; Igor Frank
Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.
The Journal of urology 2007;177(2):477-80.
2007: R Houston Thompson; Igor Frank; Christine M Lohse; Ismail R Saad; Amr Fergany; Horst Zincke; Bradley C Leibovich; Michael L Blute; Andrew C Novick
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study.
The Journal of urology 2007;177(2):471-6.
2007: Sameer A Siddiqui; Igor Frank; Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke; Michael L Blute
Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma.
The Journal of urology 2007;177(1):59-62.
2006: Amy E Krambeck; Bradley C Leibovich; Christine M Lohse; Eugene D Kwon; Horst Zincke; Michael L Blute
The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma.
The Journal of urology 2006;176(5):1990-5; discussion 1995.
2006: Haytham Dimashkieh; Christine M Lohse; Michael L Blute; Eugene D Kwon; Bradley C Leibovich; John C Cheville
Extranodal extension in regional lymph nodes is associated with outcome in patients with renal cell carcinoma.
The Journal of urology 2006;176(5):1978-82; discussion 1982-3.
2006: Alexander S Parker; Christine M Lohse; John C Cheville; David D Thiel; Bradley C Leibovich; Michael L Blute
Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma.
Urology 2006;68(4):741-6.
2006: Bradley C Leibovich; Michael L Blute
Surgical management of renal cell carcinoma.
Seminars in oncology 2006;33(5):552-62.
2006: Brant A Inman; David S DiMarco; Jeffrey M Slezak; Thomas J Sebo; Eugene D Kwon; Bradley C Leibovich; Michael L Blute; Horst Zincke
Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy.
Urology 2006;68(3):604-8.
2006: Mitchell R Humphreys; Mark H Ereth; Thomas J Sebo; Jeffrey M Slezak; Yue Dong; Michael L Blute; Matthew T Gettman
Can the kidney function as a lung? Systemic oxygenation and renal preservation during retrograde perfusion of the ischaemic kidney in rabbits.
BJU international 2006;98(3):674-9.
2006: Sameer A Siddiqui; Shomik Sengupta; Jeffrey M Slezak; Erik J Bergstralh; Horst Zincke; Michael L Blute
Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy.
The Journal of urology 2006;176(3):1118-21.
2006: R Houston Thompson; Bradley C Leibovich; John C Cheville; W Scott Webster; Christine M Lohse; Eugene D Kwon; Horst Zincke; Michael L Blute
Second primary malignancies associated with renal cell carcinoma histological subtypes.
The Journal of urology 2006;176(3):900-3; discussion 903-4.
2006: Richard A Ashley; Brant A Inman; Thomas J Sebo; Bradley C Leibovich; Michael L Blute; Eugene D Kwon; Horst Zincke
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy.
Cancer 2006;107(4):712-20.
2006: Shomik Sengupta; Carl M Christensen; Horst Zincke; Jeffrey M Slezak; Bradley C Leibovich; Erik J Bergstralh; Robert P Myers; Michael L Blute
Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
The Journal of urology 2006;176(2):559-63.
2006: Sameer A Siddiqui; Brant A Inman; Shomik Sengupta; Jeffrey M Slezak; Erik J Bergstralh; Bradley C Leibovich; Horst Zincke; Michael L Blute
Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
Cancer 2006;107(3):521-9.
2006: Amy E Krambeck; R Houston Thompson; Haidong Dong; Christine M Lohse; Eugene S Park; Susan M Kuntz; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(27):10391-6.
2006: Steven R Alberts; Paul J Novotny; Jeff A Sloan; John Danella; David G Bostwick; Thomas J Sebo; Michael L Blute; Tom R Fitch; Ralph Levitt; Ronald Lieberman; Charles L Loprinzi
Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial.
American journal of therapeutics 2006;13(4):291-7.
2006: Shomik Sengupta; John C Cheville; Christine M Lohse; Horst Zincke; Robert P Myers; Darren L Riehle; V Shane Pankratz; Michael L Blute; Thomas J Sebo
Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy.
Urology 2006;68(1):94-8.
2006: Alexander S Parker; Farhad Kosari; Christine M Lohse; R Houston Thompson; Eugene D Kwon; Linda Murphy; Darren L Riehle; Michael L Blute; Bradley C Leibovich; George Vasmatzis; John C Cheville
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
Cancer 2006;107(1):37-45.
2006: W Scott Webster; Christine M Lohse; R Houston Thompson; Haidong Dong; Xavier Frigola; Demetrius L Dicks; Shomik Sengupta; Igor Frank; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon
Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival.
Cancer 2006;107(1):46-53.
2006: Shomik Sengupta; Jeffrey M Slezak; Michael L Blute; Bradley C Leibovich; Thomas J Sebo; Robert P Myers; John C Cheville; Erik J Bergstralh; Horst Zincke
Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001.
Cancer 2006;106(12):2630-5.
2006: Matthew T Gettman; Michael L Blute
Critical comparison of laparoscopic, robotic, and open radical prostatectomy: techniques, outcomes, and cost.
Current urology reports 2006;7(3):193-9.
2006: Shomik Sengupta; Michael L Blute; Stephanie M Bagniewski; Robert P Myers; Erik J Bergstralh; Bradley C Leibovich; Horst Zincke
Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
The Journal of urology 2006;175(5):1684-90; discussion 1690.
2006: R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
Cancer research 2006;66(7):3381-5.
2006: H Barton Grossman; Michael L Blute; Colin P N Dinney; J Stephen Jones; Louis S Liou; Victor E Reuter; Mark S Soloway
The use of urine-based biomarkers in bladder cancer.
Urology 2006;67(3 Suppl 1):62-4.
2006: Shomik Sengupta; Michael L Blute
The management of superficial transitional cell carcinoma of the bladder.
Urology 2006;67(3 Suppl 1):48-54; discussion 54-5.
2006: Sameer A Siddiqui; Shomik Sengupta; Jeffrey M Slezak; Erik J Bergstralh; Bradley C Leibovich; Robert P Myers; Horst Zincke; Michael L Blute
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer.
The Journal of urology 2006;175(3 Pt 1):952-7.
2006: Shomik Sengupta; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh
Simple graphic method for estimation of prostate-specific antigen doubling time.
Urology 2006;67(2):408-9.
2006: Matthew K Tollefson; Bradley C Leibovich; Jeffrey M Slezak; Horst Zincke; Michael L Blute
Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
The Journal of urology 2006;175(2):547-51.
2006: Shomik Sengupta; Christine M Lohse; John C Cheville; Bradley C Leibovich; R Houston Thompson; W Scott Webster; Igor Frank; Horst Zincke; Michael L Blute; Eugene D Kwon
The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma.
Cancer 2006;106(2):304-12.
2006: Shomik Sengupta; John C Cheville; Christopher L Corless; Christine M Lohse; Michael C Heinrich; Eugene D Kwon; Horst Zincke; Michael L Blute; Bradley C Leibovich
Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma.
The Journal of urology 2006;175(1):53-6.
2005: Shomik Sengupta; Horst Zincke; Michael L Blute
Re: The accuracy of 250 fine needle biopsies of renal tumors.
The Journal of urology 2005;174(6):2422; author reply 2422.
2005: Shomik Sengupta; Robert P Myers; Jeffrey M Slezak; Erik J Bergstralh; Horst Zincke; Michael L Blute
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
The Journal of urology 2005;174(6):2191-6.
2005: R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Lieping Chen; Horst Zincke; Michael L Blute; Bradley C Leibovich; Eugene D Kwon
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
Cancer 2005;104(10):2084-91.
2005: Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke; Igor Frank; Eugene D Kwon; Jaime Merchan; Michael L Blute
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
The Journal of urology 2005;174(5):1759-63; discussion 1763.
2005: R Houston Thompson; W Scott Webster; John C Cheville; Christine M Lohse; Haidong Dong; Bradley C Leibovich; Susan M Kuntz; Shomik Sengupta; Eugene D Kwon; Michael L Blute
B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma.
Urology 2005;66(5 Suppl):10-4.
2005: Matthew K Tollefson; Akira Kawashima; Michael L Blute
In situ partial nephrectomy and tumor thrombectomy for renal cell carcinoma with level II vena cava extension in a solitary kidney.
Urology 2005;66(4):882.
2005: R Houston Thompson; Bradley C Leibovich; John C Cheville; W Scott Webster; Christine M Lohse; Eugene D Kwon; Igor Frank; Horst Zincke; Michael L Blute
Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?
The Journal of urology 2005;174(4 Pt 1):1218-21.
2005: R Houston Thompson; Bradley C Leibovich; Christine M Lohse; Horst Zincke; Michael L Blute
Complications of contemporary open nephron sparing surgery: a single institution experience.
The Journal of urology 2005;174(3):855-8.
2005: Shomik Sengupta; Christine M Lohse; Bradley C Leibovich; Igor Frank; R Houston Thompson; W Scott Webster; Horst Zincke; Michael L Blute; John C Cheville; Eugene D Kwon
Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.
Cancer 2005;104(3):511-20.
2005: Farhad Kosari; Alexander S Parker; Dagmar M Kube; Christine M Lohse; Bradley C Leibovich; Michael L Blute; John C Cheville; George Vasmatzis
Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(14):5128-39.
2005: Shomik Sengupta; Bradley C Leibovich; Michael L Blute; Horst Zincke
Surgery for metastatic renal cell cancer.
World journal of urology 2005;23(3):155-60.
2005: Shomik Sengupta; Horst Zincke; Bradley C Leibovich; Michael L Blute
Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series.
BJU international 2005;96(1):54-7.
2005: R Houston Thompson; John C Cheville; Christine M Lohse; W Scott Webster; Horst Zincke; Eugene D Kwon; Igor Frank; Michael L Blute; Bradley C Leibovich
Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy.
Cancer 2005;104(1):53-60.
2005: Alexander S Parker; John C Cheville; Christine M Lohse; Todd C Igel; Bradley C Leibovich; Michael L Blute
Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma.
Urology 2005;65(6):1090-5.
2005: Kristin L Chrouser; Bradley C Leibovich; Susan D Sweat; David W Larson; Brian J Davis; Nho V Tran; Horst Zincke; Michael L Blute
Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer.
The Journal of urology 2005;173(6):1953-7.
2005: Michael D Gillett; John C Cheville; R Jeffrey Karnes; Christine M Lohse; Eugene D Kwon; Bradley C Leibovich; Horst Zincke; Michael L Blute
Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses.
The Journal of urology 2005;173(6):1893-6.
2005: Igor Frank; Michael L Blute; Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke
Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.
The Journal of urology 2005;173(6):1889-92.
2005: Amy E Krambeck; Dylan V Miller; Michael L Blute
Wegener's granulomatosis presenting as renal mass: a case for nephron-sparing surgery.
Urology 2005;65(4):798.
2005: John Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
BJU international 2005;95(6):751-6.
2005: John Ward; Thomas J Sebo; Michael L Blute; Horst Zincke
Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes.
The Journal of urology 2005;173(4):1156-60.
2005: David S DiMarco; Horst Zincke; Thomas J Sebo; Jeffrey Slezak; Erik J Bergstralh; Michael L Blute
The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
The Journal of urology 2005;173(4):1121-5.
2005: R Houston Thompson; Bradley C Leibovich; John C Cheville; Christine M Lohse; Igor Frank; Eugene D Kwon; Horst Zincke; Michael L Blute
Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?
The Journal of urology 2005;173(3):918-21.
2005: Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke; Eugene D Kwon; Igor Frank; R Houston Thompson; Michael L Blute
Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?
The Journal of urology 2005;173(3):716-9.
2005: Ahmad H Bani-Hani; Bradley C Leibovich; Christine M Lohse; John C Cheville; Horst Zincke; Michael L Blute
Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients.
The Journal of urology 2005;173(2):391-4.
2005: Igor Frank; Michael L Blute; Bradley C Leibovich; John C Cheville; Christine M Lohse; Eugene D Kwon; Horst Zincke
pT2 classification for renal cell carcinoma. Can its accuracy be improved?
The Journal of urology 2005;173(2):380-4.
2004: R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(49):17174-9.
2004: Michael D Gillett; Matthew T Gettman; Horst Zincke; Michael L Blute
Tissue ablation technologies for localized prostate cancer.
Mayo Clinic proceedings. Mayo Clinic 2004;79(12):1547-55.
2004: Haytham Dimashkieh; Dragan Jevremovic; Michael L Blute; Donna J Lager
Pathologic quiz case: a 56-year-old man with bilateral renal masses. Bilateral renal oncocytosis.
Archives of pathology & laboratory medicine 2004;128(12):e177-8.
2004: John Ward; Horst Zincke; Erik J Bergstralh; Jeffrey M Slezak; Michael L Blute
Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.
The Journal of urology 2004;172(6 Pt 1):2244-8.
2004: Daniel J Schaid; Jennifer C Guenther; Gerald B Christensen; Scott J Hebbring; Carsten Rosenow; Christopher A Hilker; Shannon K McDonnell; Julie M Cunningham; Susan L Slager; Michael L Blute; Stephen N Thibodeau
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci.
American journal of human genetics 2004;75(6):948-65.
2004: Matthew T Gettman; Michael L Blute; George K Chow; Richard Neururer; Georg Bartsch; Reinhard Peschel
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system.
Urology 2004;64(5):914-8.
2004: Igor Frank; John C Cheville; Michael L Blute; Christine M Lohse; R Jeffrey Karnes; Amy L Weaver; Thomas J Sebo; Ajay Nehra; Horst Zincke
Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
Cancer 2004;101(8):1803-8.
2004: John Ward; Horst Zincke; Erik J Bergstralh; Jeffrey M Slezak; Robert P Myers; Michael L Blute
The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy.
The Journal of urology 2004;172(4 Pt 1):1328-32.
2004: Mitchell R Humphreys; Matthew T Gettman; George K Chow; Horst Zincke; Michael L Blute
Minimally invasive radical prostatectomy.
Mayo Clinic proceedings. Mayo Clinic 2004;79(9):1169-80.
2004: David S DiMarco; Christine M Lohse; Horst Zincke; John C Cheville; Michael L Blute
Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
Urology 2004;64(3):462-7.
2004: John C Cheville; Igor Frank; Bradley C Leibovich; Christine M Lohse; Michael L Blute
Re: Renal vein or inferior vena caval extension in patients with renal cortical tumors: impact of tumor histology.
The Journal of urology 2004;172(3):1196; author reply 1196.
2004: Jess L Thompson; Michael L Blute
Coffee grounds emesis: rare presentation of testicular cancer treated with neoadjuvant chemotherapy.
Urology 2004;64(2):376-7.
2004: Michael L Blute; Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke
A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.
The Journal of urology 2004;172(2):465-9.
2004: Michael L Blute; Bradley C Leibovich; Christine M Lohse; John C Cheville; Horst Zincke
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus.
BJU international 2004;94(1):33-41.
2004: John Ward; Michael L Blute
Use and timing of radiotherapy in high-risk prostate cancer.
JAMA : the journal of the American Medical Association 2004;291(23):2817; author reply 2817-8.
2004: Alexander S Parker; John C Cheville; Michael L Blute; Todd C Igel; Christine M Lohse; James Cerhan
Pathologic T1 clear cell renal cell carcinoma: insulin-like growth factor-I receptor expression and disease-specific survival.
Cancer 2004;100(12):2577-82.
2004: John C Cheville; Christine M Lohse; Horst Zincke; Amy L Weaver; Bradley C Leibovich; Igor Frank; Michael L Blute
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome.
The American journal of surgical pathology 2004;28(4):435-41.
2004: Daniel R Brown; Roger E Hofer; David E Patterson; Paul J Fronapfel; Pamela M Maxson; Bradly J Narr; John H Eisenach; Michael L Blute; Darrell R Schroeder; David O Warner
Intrathecal anesthesia and recovery from radical prostatectomy: a prospective, randomized, controlled trial.
Anesthesiology 2004;100(4):926-34.
2004: Charles Y F Young; Aminah Jatoi; John Ward; Michael L Blute
The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer.
Current medicinal chemistry 2004;11(7):909-23.
2004: Bruce J Trock; Michelle Brotzman; William J Utz; Roland R Ugarte; Steven A Kaplan; Thayne R Larson; Michael L Blute; Claus G Roehrborn; Alan W Partin
Long-term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia results at three months through four years.
Urology 2004;63(4):716-21.
2004: Nelson Leung; Steven R Ytterberg; Michael L Blute; Donna J Lager; Ulrich Specks; Fernando C Fervenza
Wegener's granulomatosis presenting as multiple bilateral renal masses.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2004;19(4):984-7.
2004: Igor Frank; Michael L Blute
Defining the appropriate patient population for primary brachytherapy for localized prostate cancer: work in progress.
Mayo Clinic proceedings. Mayo Clinic 2004;79(3):307-8.
2004: Michael L Blute; Erik Bergstralh
Re: Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the Search database.
The Journal of urology 2004;171(2 Pt 1):808; author reply 808-9.
2004: John Ward; George Bartsch; Thomas J Sebo; Germar-M. Pinggera; Michael L Blute; Horst Zincke
Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?
Urologic oncology 2004;22(1):40-7.
2003: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Bradley C Leibovich; Horst Zincke
A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma.
The Journal of urology 2003;170(6 Pt 1):2225-32.
2003: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Solid renal tumors: an analysis of pathological features related to tumor size.
The Journal of urology 2003;170(6 Pt 1):2217-20.
2003: Julie M Cunningham; Shannon K McDonnell; Angela Marks; Scott J Hebbring; Sarah A Anderson; Brett J Peterson; Susan L Slager; Amy French; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau
Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study.
The Prostate 2003;57(4):335-46.
2003: David S DiMarco; Michael L Blute; Horst Zincke; John C Cheville; Darren L Riehle; Christine M Lohse; V Shane Pankratz; Thomas J Sebo
Multivariate models to predict clinically important outcomes at prostatectomy for patients with organ-confined disease and needle biopsy Gleason scores of 6 or less.
Urologic oncology 2003;21(6):439-46.
2003: Michael A Farrell; J William Charboneau; Matthew R Callstrom; Carl C Reading; D E Engen; Michael L Blute
Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation.
AJR. American journal of roentgenology 2003;181(5):1315-7.
2003: John Ward; Michael L Blute; Jeffrey Slezak; Erik J Bergstralh; Horst Zincke
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
The Journal of urology 2003;170(5):1872-6.
2003: Kent G Krejci; Michael L Blute; John C Cheville; Thomas J Sebo; Christine M Lohse; Horst Zincke
Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
Urology 2003;62(4):641-6.
2003: Liang Wang; Shannon K McDonnell; Julie M Cunningham; Scott J Hebbring; Steven J Jacobsen; James Cerhan; Susan L Slager; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau
No association of germline alteration of MSR1 with prostate cancer risk.
Nature genetics 2003;35(2):128-9.
2003: Alexander Parker; John C Cheville; Christine Lohse; James Cerhan; Michael L Blute
Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma.
The Journal of urology 2003;170(2 Pt 1):420-4.
2003: George K Chow; David E Patterson; Michael L Blute; Joseph W Segura
Ureteroscopy: effect of technology and technique on clinical practice.
The Journal of urology 2003;170(1):99-102.
2003: Weber K Lau; Horst Zincke; Christine M Lohse; John C Cheville; Amy L Weaver; Michael L Blute
Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review.
BJU international 2003;91(9):775-9.
2003: Igor Frank; John C Cheville; Michael L Blute; Christine M Lohse; Ajay Nehra; Amy L Weaver; R Jeffrey Karnes; Horst Zincke
Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome.
Cancer 2003;97(10):2425-31.
2003: John C Cheville; Christine M Lohse; Horst Zincke; Amy L Weaver; Michael L Blute
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma.
The American journal of surgical pathology 2003;27(5):612-24.
2003: John Ward; Michael L Blute
Chemoprevention of prostate cancer.
Expert review of anticancer therapy 2003;3(2):203-14.
2003: Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Igor Frank; Eugene D Kwon; Amy L Weaver; Alexander S Parker; Horst Zincke
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Cancer 2003;97(7):1663-71.
2003: Matthew T Gettman; Christopher W Boelter; John C Cheville; Horst Zincke; Sandra C Bryant; Michael L Blute
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension.
The Journal of urology 2003;169(4):1282-6.
2003: Michael L Blute; Nancy B Itano; John C Cheville; Amy L Weaver; Christine M Lohse; Horst Zincke
The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
The Journal of urology 2003;169(4):1276-81.
2003: Matthew T Gettman; Michael L Blute; Reinhard Peschel; Georg Bartsch
Current status of robotics in urologic laparoscopy.
European urology 2003;43(2):106-12.
2003: Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M Cunningham; Shannon K McDonnell; Chiping Qian; Angela F Marks; Susan L Slager; Brett J Peterson; David I Smith; John C Cheville; Michael L Blute; Steve J Jacobsen; Daniel J Schaid; Donald J Tindall; Stephen N Thibodeau; Wanguo Liu
Mutations in CHEK2 associated with prostate cancer risk.
American journal of human genetics 2003;72(2):270-80.
2003: Christopher B Dechet; Horst Zincke; Thomas J Sebo; Bernard F King; Andrew J LeRoy; George M Farrow; Michael L Blute
Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults.
The Journal of urology 2003;169(1):71-4.
2002: Gregory A Nuttall; Michael D Cragun; Darin L Hill; Ted J Morris; Paul A Decker; Michael L Blute; David E Patterson; David O Warner
Radical retropubic prostatectomy and blood transfusion.
Mayo Clinic proceedings. Mayo Clinic 2002;77(12):1301-5.
2002: Christine M Lohse; Michael L Blute; Horst Zincke; Amy L Weaver; John C Cheville
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients.
American journal of clinical pathology 2002;118(6):877-86.
2002: Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.
The Journal of urology 2002;168(6):2395-400.
2002: Sankar J Kausik; Michael L Blute; Thomas J Sebo; Bradley C Leibovich; Erik J Bergstralh; Jeff Slezak; Horst Zincke
Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy.
Cancer 2002;95(6):1215-9.
2002: John C Cheville; Donald Tindall; Christopher Boelter; Robert Jenkins; Christine M Lohse; V Shane Pankratz; Thomas J Sebo; Brian Davis; Michael L Blute
Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cancer 2002;95(5):1028-36.
2002: Steven J Jacobsen; Stephen N Thibodeau; Shannon K McDonnell; Brett J Peterson; Erik J Bergstralh; Daniel J Schaid; Michael L Blute
Lack of referral bias in genetic studies of prostate cancer.
Epidemiology (Cambridge, Mass.) 2002;13(5):612-3.
2002: Thomas M Pisansky; Michael L Blute; David W Hillman; Brian J Davis; Michael G Haddock; Vera J Suman; Torrence M Wilson; Horst Zincke
The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma.
Cancer 2002;95(3):513-9.
2002: Matthew T Gettman; Michael L Blute
Update on pathologic staging of renal cell carcinoma.
Urology 2002;60(2):209-17.
2002: Michael P O'Leary; Neil H Baum; Richard Blizzard; Michael L Blute; Thomas P Cooper; Martin K Dineen; Randy B Fenninger; William F Gee; E Ann Gormley; Jeffrey M Ignatoff; Daniel A Nachtsheim; M Ray Painter; Raju Thomas; John T Wei
2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction.
The Journal of urology 2002;168(2):649-52.
2002: Susan D Sweat; Erik J Bergstralh; Jeffrey Slezak; Michael L Blute; Horst Zincke
Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
The Journal of urology 2002;168(2):525-9.
2002: Reza Ghavamian; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke; Michael L Blute
Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery.
The Journal of urology 2002;168(2):454-9.
2002: John Ward; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
The Journal of urology 2002;168(1):56-60.
2002: Liang Wang; Shannon K McDonnell; David A Elkins; Susan L Slager; Eric Christensen; Angela F Marks; Julie M Cunningham; Brett J Peterson; Steven J Jacobsen; James Cerhan; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau
Analysis of the RNASEL gene in familial and sporadic prostate cancer.
American journal of human genetics 2002;71(1):116-23.
2002: Kevin C Halling; Walter King; Irina A Sokolova; R Jeffrey Karnes; Reid G Meyer; Eric L Powell; Thomas J Sebo; John C Cheville; Amy C Clayton; Kelly L Krajnik; Thomas A Ebert; Robert E Nelson; Haleh M Burkhardt; Sanjay Ramakumar; Christopher S Stewart; V Shane Pankratz; Michael M Lieber; Michael L Blute; Horst Zincke; Steven A Seelig; Robert B Jenkins; Dennis J O'Kane
A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
The Journal of urology 2002;167(5):2001-6.
2002: John C Cheville; Horst Zincke; Christine M Lohse; Thomas J Sebo; Darren Riehle; Amy L Weaver; Michael L Blute
pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cancer 2002;94(8):2180-4.
2002: Weber K Lau; John C Cheville; Michael L Blute; Amy L Weaver; Horst Zincke
Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
Urology 2002;59(4):532-7.
2002: Thomas J Sebo; John C Cheville; Darren L Riehle; Christine M Lohse; V Shane Pankratz; Robert P Myers; Michael L Blute; Horst Zincke
Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer.
The American journal of surgical pathology 2002;26(4):431-9.
2002: Matthew T Gettman; Michael L Blute
Surgical management of renal cell carcinoma invading the vena cava.
Current urology reports 2002;3(1):37-43.
2002: Seth E Lerner; Craig A Hawkins; Michael L Blute; Andreas Grabner; Peter Wollan; Jeffrey T Eickholt; Horst Zincke
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. 1996.
The Journal of urology 2002;167(2 Pt 2):884-9; discussion 889-90.
2002: Michael J Manyak; Stacey J Ackerman; Michael L Blute; Alison L Rein; Kathleen Buesterien; Erin M Sullivan; CRAIG TANIO; Michael J Strauss
Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive, and surgical therapy.
Journal of endourology / Endourological Society 2002;16(1):51-6.
2002: Weber K Lau; Erik J Bergstralh; Michael L Blute; Jeffrey M Slezak; Horst Zincke
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
The Journal of urology 2002;167(1):117-22.
2001: Michael L Blute; Thayne Larson
Minimally invasive therapies for benign prostatic hyperplasia.
Urology 2001;58(6 Suppl 1):33-40; discussion 40-1.
2001: Horst Zincke; W Lau; Erik J Bergstralh; Michael L Blute
Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
The Journal of urology 2001;166(6):2208-15.
2001: Liang Wang; Shannon K McDonnell; David A Elkins; Susan L Slager; Eric Christensen; Angela F Marks; Julie M Cunningham; Brett J Peterson; Steven J Jacobsen; James Cerhan; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau
Role of HPC2/ELAC2 in hereditary prostate cancer.
Cancer research 2001;61(17):6494-9.
2001: Daniel S Elliott; Joseph W Segura; Deborah Lightner; David E Patterson; Michael L Blute
Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney.
Urology 2001;58(2):174-8.
2001: S G Roberts; Michael L Blute; Erik J Bergstralh; Jeffrey M Slezak; Horst Zincke
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Mayo Clinic proceedings. Mayo Clinic 2001;76(6):576-81.
2001: Thomas J Sebo; John C Cheville; Darren L Riehle; Christine M Lohse; V Shane Pankratz; Robert P Myers; Michael L Blute; Horst Zincke
Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
Cancer 2001;91(11):2196-204.
2001: Matthew T Gettman; Michael L Blute; B Spotts; Sandra C Bryant; Horst Zincke
Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system.
Cancer 2001;91(2):354-61.
2001: Liang Cheng; Horst Zincke; Michael L Blute; Erik J Bergstralh; BG Scherer; David G Bostwick
Risk of prostate carcinoma death in patients with lymph node metastasis.
Cancer 2001;91(1):66-73.
2001: Michael L Blute; Erik J Bergstralh; A Iocca; B Scherer; Horst Zincke
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
The Journal of urology 2001;165(1):119-25.
2000: Michael L Blute; Stacey J Ackerman; Alison L Rein; Kathleen M Beusterien; Erin M Sullivan; CRAIG TANIO; Michael J Strauss; Michael J Manyak
Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part II--results.
Urology 2000;56(6):981-7.
2000: Stacey J Ackerman; Alison L Rein; Michael L Blute; Kathleen M Beusterien; Erin M Sullivan; CRAIG TANIO; Michael J Manyak; Michael J Strauss
Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods.
Urology 2000;56(6):972-80.
2000: W K Lau; Michael L Blute; A L Weaver; V E Torres; Horst Zincke
Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney.
Mayo Clinic proceedings. Mayo Clinic 2000;75(12):1236-42.
2000: Bradley C Leibovich; Michael L Blute; David G Bostwick; Torrence M Wilson; Thomas M Pisansky; Brian J Davis; DM Ramnani; Liang Cheng; Thomas J Sebo; Horst Zincke
Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.
Urology 2000;56(5):726-9.
2000: Michael L Blute; E J Bergstralh; Alan W Partin; Patrick C Walsh; Michael W Kattan; Peter T Scardino; James E Montie; Jay D Pearson; J M Slezak; Horst Zincke
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
The Journal of urology 2000;164(5):1591-5.
2000: Michael L Blute; Christopher L Amling; Sandra C Bryant; Horst Zincke
Management and extended outcome of patients with synchronous bilateral solid renal neoplasms in the absence of von Hippel-Lindau disease.
Mayo Clinic proceedings. Mayo Clinic 2000;75(10):1020-6.
2000: Michael P O'Leary; William F Gee; HL Holtgrewe; Michael L Blute; Thomas P Cooper; BJ Miles; RE Nellans; Raju Thomas; M Ray Painter; JJ Meyer; Michael J Naslund; E Ann Gormley; Richard Blizzard; Randy B Fenninger
1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care.
The Journal of urology 2000;164(4):1311-6.
2000: N B Itano; Michael L Blute; B Spotts; Horst Zincke
Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
The Journal of urology 2000;164(2):322-5.
2000: Christopher L Amling; Michael L Blute; Erik J Bergstralh; T M Seay; Jeffrey Slezak; Horst Zincke
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
The Journal of urology 2000;164(1):101-5.
2000: M K Knight; Michael L Blute
Incidental discovery of pelvic leiomyosarcoma at radical prostatectomy.
The Journal of urology 2000;163(6):1866.
2000: Liang Cheng; R V Lloyd; AL Weaver; Thomas M Pisansky; JC Cheville; DM Ramnani; Bradley C Leibovich; Michael L Blute; Horst Zincke; David G Bostwick
The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1896-9.
2000: Bradley C Leibovich; Donald Engen; D E Patterson; Thomas M Pisansky; E E Alexander; Michael L Blute; Erik J Bergstralh; Horst Zincke
Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.
The Journal of urology 2000;163(4):1178-82.
2000: Thomas M Pisansky; Timothy F Kozelsky; Robert P Myers; D W Hillman; Michael L Blute; Steven J. Buskirk; John C Cheville; Robert G Ferrigni; Steven E Schild
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
The Journal of urology 2000;163(3):845-50.
2000: R Berry; Daniel J Schaid; J R Smith; Amy J French; JJ Schroeder; Shannon K McDonnell; Brett J Peterson; Z Y Wang; J D Carpten; S G Roberts; David J Tester; Michael L Blute; Jeffrey M. Trent; Stephen N Thibodeau
Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer.
American journal of human genetics 2000;66(2):539-46.
1999: Michael P O'Leary; William F Gee; HL Holtgrewe; Michael L Blute; Thomas P Cooper; JJ Meyer; BJ Miles; Michael J Naslund; RE Nellans; Raju Thomas; M Ray Painter; Richard Blizzard; Randy B Fenninger
1998 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of ureteral stones and impact of managed care.
The Journal of urology 1999;162(5):1702-4.
1999: Liang Cheng; Thomas M Pisansky; Thomas J Sebo; Bradley C Leibovich; DM Ramnani; AL Weaver; BG Scherer; Michael L Blute; Horst Zincke; David G Bostwick
Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2820-3.
1999: CB Dechet; Thomas J Sebo; George M Farrow; Michael L Blute; D E Engen; Horst Zincke
Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults.
The Journal of urology 1999;162(4):1282-4; discussion 1284-5.
1999: Matthew T Gettman; Anna Pacelli; Jeffrey Slezak; Erik J Bergstralh; Michael L Blute; Horst Zincke; David G Bostwick
Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Urology 1999;54(3):479-85.
1999: Reza Ghavamian; Michael L Blute; Erik J Bergstralh; Jeffrey Slezak; Horst Zincke
Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
Urology 1999;54(1):105-10.
1999: CB Dechet; David G Bostwick; Michael L Blute; Sandra C Bryant; Horst Zincke
Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma.
The Journal of urology 1999;162(1):40-2.
1999: Reza Ghavamian; Erik J Bergstralh; Michael L Blute; Jeffrey Slezak; Horst Zincke
Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison.
The Journal of urology 1999;161(4):1223-7; discussion 1227-8.
1999: Liang Cheng; Erik J Bergstralh; BG Scherer; RM Neumann; Michael L Blute; Horst Zincke; David G Bostwick
Predictors of cancer progression in T1a prostate adenocarcinoma.
Cancer 1999;85(6):1300-4.
1999: Christopher L Amling; SE Lerner; SK Martin; Jeffrey M Slezak; Michael L Blute; Horst Zincke
Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
The Journal of urology 1999;161(3):857-62; discussion 862-3.
1999: F A Corica; Kenneth A Iczkowski; L Cheng; Horst Zincke; Michael L Blute; A Wendel; Thomas J Sebo; R Neumann; David G Bostwick
Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup.
The Journal of urology 1999;161(2):408-11.
1999: Sanjay Ramakumar; J Bhuiyan; J A Besse; S G Roberts; P C Wollan; Michael L Blute; Dennis J O'Kane
Comparison of screening methods in the detection of bladder cancer.
The Journal of urology 1999;161(2):388-94.
1998: Liang Cheng; Erik J Bergstralh; JC Cheville; Jeffrey Slezak; F A Corica; Horst Zincke; Michael L Blute; David G Bostwick
Cancer volume of lymph node metastasis predicts progression in prostate cancer.
The American journal of surgical pathology 1998;22(12):1491-500.
1998: William F Gee; HL Holtgrewe; Michael L Blute; BJ Miles; Michael J Naslund; RE Nellans; Michael P O'Leary; Raju Thomas; M Ray Painter; JJ Meyer; T J Rohner; Thomas P Cooper; Richard Blizzard; Randy B Fenninger; L Emmons
1997 American Urological Association Gallup survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997.
The Journal of urology 1998;160(5):1804-7.
1998: B M Gburek; Michael M Lieber; Michael L Blute
Comparison of studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications.
The Journal of urology 1998;160(3 Pt 1):721-3.
1998: Michael L Blute; Thayne R Larson; K A Hanson; BF King
Current status of transurethral thermotherapy at the Mayo Clinic.
Mayo Clinic proceedings. Mayo Clinic 1998;73(6):597-602.
1998: Michael L Blute; B M Gburek
Continent orthotopic urinary diversion in female patients: early Mayo Clinic experience.
Mayo Clinic proceedings. Mayo Clinic 1998;73(6):501-7.
1998: David G Bostwick; Anna Pacelli; Michael L Blute; P Roche; G P Murphy
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Cancer 1998;82(11):2256-61.
1998: Daniel J Schaid; Shannon K McDonnell; Michael L Blute; Stephen N Thibodeau
Evidence for autosomal dominant inheritance of prostate cancer.
American journal of human genetics 1998;62(6):1425-38.
1998: Christopher L Amling; Michael L Blute; SE Lerner; Erik J Bergstralh; D G Bostwick; Horst Zincke
Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.
Mayo Clinic proceedings. Mayo Clinic 1998;73(5):401-6.
1998: A Lopez-Beltran; Anna Pacelli; Harold J Rothenberg; P C Wollan; Horst Zincke; Michael L Blute; David G Bostwick
Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases.
The Journal of urology 1998;159(5):1497-503.
1998: Michael L Blute; David G Bostwick; T M Seay; SK Martin; Jeffrey M Slezak; Erik J Bergstralh; Horst Zincke
Pathologic classification of prostate carcinoma: the impact of margin status.
Cancer 1998;82(5):902-8.
1998: T M Seay; Michael L Blute; Horst Zincke
Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation.
The Journal of urology 1998;159(2):357-64.
1998: James A Brown; Joseph W Segura; Michael L Blute
A giant left renal cyst presenting as obesity: a unique presentation.
Archivos españoles de urología 1998;51(1):105-7.
1998: Matthew T Gettman; Erik J Bergstralh; Michael L Blute; Horst Zincke; David G Bostwick
Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis.
Urology 1998;51(1):79-85.
1997: Christopher L Amling; Michael L Blute; Erik J Bergstralh; Jeffrey M Slezak; SK Martin; Horst Zincke
Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer.
Seminars in urologic oncology 1997;15(4):222-9.
1997: Christopher L Amling; B C Leibovich; SE Lerner; Erik J Bergstralh; Michael L Blute; R P Myers; Horst Zincke
Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate.
Seminars in urologic oncology 1997;15(4):215-21.
1997: Michael L Blute; David G Bostwick; Erik J Bergstralh; Jeffrey M Slezak; SK Martin; Christopher L Amling; Horst Zincke
Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
Urology 1997;50(5):733-9.
1997: S Störkel; J N Eble; K Adlakha; Mahul B Amin; Michael L Blute; David G Bostwick; M Darson; B Delahunt; Kenneth A Iczkowski
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).
Cancer 1997;80(5):987-9.
1997: M J vander Kooy; Thomas M Pisansky; S S Cha; Michael L Blute
Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy.
Urology 1997;49(1):65-70.
1997: W J Harmon; P D Sershon; Michael L Blute; David E Patterson; Joseph W Segura
Ureteroscopy: current practice and long-term complications.
The Journal of urology 1997;157(1):28-32.
1996: Michael L Blute; David E Patterson; Joseph W Segura; K M Tomera; D K Hellerstein
Transurethral microwave thermotherapy v sham treatment: double-blind randomized study.
Journal of endourology / Endourological Society 1996;10(6):565-73.
1996: Thomas M Pisansky; Michael L Blute; Vera J Suman; D G Bostwick; John D Earle; Horst Zincke
Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens.
International journal of radiation oncology, biology, physics 1996;36(3):585-91.
1996: S E Lerner; Michael L Blute; R L Richardson; Horst Zincke
Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract.
Mayo Clinic proceedings. Mayo Clinic 1996;71(10):945-50.
1996: S E Lerner; S J Jacobsen; Hans Lilja; Erik J Bergstralh; J Ransom; George G Klee; Timo Piironen; Michael L Blute; Michael M Lieber; Horst Zincke; Kim Pettersson; D Peterson; JE Oesterling
Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.
Urology 1996;48(2):240-8.
1996: David G Bostwick; T M Wheeler; Michael L Blute; D M Barrett; G T MacLennan; Thomas J Sebo; Peter T Scardino; P A Humphrey; M A Hudson; Y Fradet; G J Miller; E D Crawford; Brent Blumenstein; H E Mahran; B J Miles
Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies.
Urology 1996;48(1):47-57.
1996: S E Lerner; Michael L Blute; Erik J Bergstralh; David G Bostwick; J T Eickholt; Horst Zincke
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
The Journal of urology 1996;156(1):137-43.
1996: D S Elliott; Michael L Blute; D E Patterson; Erik J Bergstralh; Joseph W Segura
Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma.
Urology 1996;47(6):819-25.
1996: S E Lerner; C A Hawkins; Michael L Blute; A Grabner; P C Wollan; J T Eickholt; Horst Zincke
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery.
The Journal of urology 1996;155(6):1868-73.
1996: B A Kletscher; Junqi Qian; David G Bostwick; Michael L Blute; Horst Zincke
Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma.
The Journal of urology 1996;155(6):1844-6.
1996: S E Lerner; Michael L Blute; Horst Zincke
Risk factors for progression in patients with prostate cancer treated with radical prostatectomy.
Seminars in urologic oncology 1996;14(2 Suppl 2):12-20; discussion 21.
1996: S E Lerner; T M Seay; Michael L Blute; Erik J Bergstralh; D Barrett; Horst Zincke
Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
The Journal of urology 1996;155(3):821-6.
1995: S E Lerner; Michael L Blute; Horst Zincke
Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity.
The Journal of urology 1995;154(4):1447-52.
1995: S E Lerner; B S Mann; Michael L Blute; R L Richardson; Horst Zincke
Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results.
Mayo Clinic proceedings. Mayo Clinic 1995;70(9):821-8.
1995: S E Lerner; Michael L Blute; Horst Zincke
Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer.
The Journal of urology 1995;154(3):1103-9.
1994: Horst Zincke; Erik J Bergstralh; Michael L Blute; R P Myers; D M Barrett; M M Lieber; SK Martin; JE Oesterling
Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(11):2254-63.
1994: Horst Zincke; JE Oesterling; Michael L Blute; Erik J Bergstralh; R P Myers; David M Barrett
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.
The Journal of urology 1994;152(5 Pt 2):1850-7.
1994: Michael L Blute
Microwave thermotherapy for the treatment of benign prostatic hyperplasia.
Seminars in urology 1994;12(3):181-92.
1994: Vicente E Torres; B F King; K E Holley; Michael L Blute; M R Gomez
The kidney in the tuberous sclerosis complex.
Advances in nephrology from the Necker Hospital 1994;23():43-70.
1993: Michael L Blute; K M Tomera; D K Hellerstein; C F McKiel; J H Lynch; J B Regan; N E Sankey
Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study.
The Journal of urology 1993;150(5 Pt 2):1591-6.
1993: D A Guthman; T M Wilson; Michael L Blute; Erik J Bergstralh; Horst Zincke; J E Oesterling
Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics.
Urology 1993;42(2):150-4.
1993: L A Kerr; Michael L Blute; J H Ryu; S J Swensen; Reza S Malek
Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis: forme fruste of tuberous sclerosis?
Urology 1993;41(5):440-4.
1993: T J Stormont; George M Farrow; R P Myers; Michael L Blute; Horst Zincke; T M Wilson; JE Oesterling
Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration.
Urology 1993;41(1):3-8.
1992: Michael L Blute; K M Tomera; D K Hellerstein; E J Atkinson; David E Patterson; Joseph W Segura
Transurethral microwave thermotherapy for prostatism: early Mayo Foundation experience.
Mayo Clinic proceedings. Mayo Clinic 1992;67(5):417-21.
1991: Horst Zincke; Michael L Blute; M J Fallen; George M Farrow
Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome.
The Journal of urology 1991;146(4):1053-8.
1990: L R Strawbridge; Michael L Blute; E M James; D J Gillespie
Intraoperative ultrasonographically guided biopsy in testicular sarcoidosis: a case report.
The Journal of urology 1990;143(6):1229-31.
1990: B T Montgomery; O Nativ; Michael L Blute; George M Farrow; R P Myers; Horst Zincke; T M Therneau; Michael M Lieber
Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis.
Archives of surgery (Chicago, Ill. : 1960) 1990;125(3):327-31.
1989: Michael L Blute; O Nativ; Horst Zincke; George M Farrow; T Therneau; Michael M Lieber
Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy.
The Journal of urology 1989;142(5):1262-5.
1989: Michael L Blute; Joseph W Segura; David E Patterson; R C Benson; Horst Zincke
Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer.
The Journal of urology 1989;141(6):1298-301.
1989: Michael L Blute; D E Engen; William D Travis; L K Kvols
Primary signet ring cell adenocarcinoma of the bladder.
The Journal of urology 1989;141(1):17-21.
1988: Michael L Blute; K Tsushima; George M Farrow; T M Therneau; Michael M Lieber
Transitional cell carcinoma of the renal pelvis: nuclear deoxyribonucleic acid ploidy studied by flow cytometry.
The Journal of urology 1988;140(5):944-9.
1988: Michael L Blute; Joseph W Segura; David E Patterson
Ureteroscopy.
The Journal of urology 1988;139(3):510-2.
1988: Michael L Blute; Reza S Malek; Joseph W Segura
Angiomyolipoma: clinical metamorphosis and concepts for management.
The Journal of urology 1988;139(1):20-4.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.